Paratek Pharmaceuticals Probability of Future Stock Price Finishing Over 2.21

PRTKDelisted Stock  USD 2.23  0.00  0.00%   
Paratek Pharmaceuticals' future price is the expected price of Paratek Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Paratek Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
  
Please specify Paratek Pharmaceuticals' target price for which you would like Paratek Pharmaceuticals odds to be computed.

Paratek Pharmaceuticals Target Price Odds to finish over 2.21

The tendency of Paratek Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 2.21  in 90 days
 2.23 90 days 2.21 
about 24.06
Based on a normal probability distribution, the odds of Paratek Pharmaceuticals to stay above $ 2.21  in 90 days from now is about 24.06 (This Paratek Pharmaceuticals probability density function shows the probability of Paratek Stock to fall within a particular range of prices over 90 days) . Probability of Paratek Pharmaceuticals price to stay between $ 2.21  and its current price of $2.23 at the end of the 90-day period is about 22.33 .
Given the investment horizon of 90 days Paratek Pharmaceuticals has a beta of -0.0963 indicating as returns on the benchmark increase, returns on holding Paratek Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Paratek Pharmaceuticals is likely to outperform the market. Additionally Paratek Pharmaceuticals has an alpha of 0.0242, implying that it can generate a 0.0242 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   Paratek Pharmaceuticals Price Density   
       Price  

Predictive Modules for Paratek Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Paratek Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Paratek Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
2.232.232.23
Details
Intrinsic
Valuation
LowRealHigh
1.881.882.45
Details
Naive
Forecast
LowNextHigh
2.222.222.22
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.172.222.25
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Paratek Pharmaceuticals. Your research has to be compared to or analyzed against Paratek Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Paratek Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Paratek Pharmaceuticals.

Paratek Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Paratek Pharmaceuticals is not an exception. The market had few large corrections towards the Paratek Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Paratek Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Paratek Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
0.02
β
Beta against NYSE Composite-0.1
σ
Overall volatility
0.01
Ir
Information ratio -0.04

Paratek Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Paratek Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Paratek Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Paratek Pharmaceuticals is not yet fully synchronised with the market data
Paratek Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 150.79 M. Net Loss for the year was (63.57 M) with profit before overhead, payroll, taxes, and interest of 99.39 M.
Paratek Pharmaceuticals currently holds about 57.01 M in cash with (66.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03.
Roughly 55.0% of the company shares are owned by institutional investors

Paratek Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Paratek Stock often depends not only on the future outlook of the current and potential Paratek Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Paratek Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding54.4 M
Cash And Short Term Investments34.2 M

Paratek Pharmaceuticals Technical Analysis

Paratek Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Paratek Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Paratek Pharmaceuticals. In general, you should focus on analyzing Paratek Stock price patterns and their correlations with different microeconomic environments and drivers.

Paratek Pharmaceuticals Predictive Forecast Models

Paratek Pharmaceuticals' time-series forecasting models is one of many Paratek Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Paratek Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Paratek Pharmaceuticals

Checking the ongoing alerts about Paratek Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Paratek Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Paratek Pharmaceuticals is not yet fully synchronised with the market data
Paratek Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 150.79 M. Net Loss for the year was (63.57 M) with profit before overhead, payroll, taxes, and interest of 99.39 M.
Paratek Pharmaceuticals currently holds about 57.01 M in cash with (66.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03.
Roughly 55.0% of the company shares are owned by institutional investors
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities